Laurus Labs Limited (LAURUSLABS): research summary
Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Laurus Labs Limited, explained in plain English.
- Laurus Labs Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
- LAURUSLABS closed at ₹2,306.00 on 19 November 2026.
- Over the past year the shares are up 133.5%, trading between ₹917.95 and ₹2,488.00.
- Reported fundamentals show return on equity of 23.97%, a net margin of 17.13%, debt to equity of 42.47.
- Our Pulse grade checklist scores it A (88/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
- Annualised volatility over the past year is 31.85% with a maximum drawdown of -16.27% and a beta of 0.66 against NIFTY 50.
- Recent coverage: HDFC Bank Share Price Live Updates: HNIs now own a record Rs 10 lakh crore worth of Indian stocks. Laurus Labs, Cupid among top 10 favourites
- Recent coverage: Prime Focus among 4 stocks that closed above VWAP
- Recent coverage: Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma
Last traded values from 19 Nov 2026. Market opens at 9:15 IST.
Pharma & Healthcare · Drug Manufacturers - Specialty & Generic
Laurus Labs Limited (LAURUSLABS)
₹2,322.5
▼ 15.5 (-0.66%)Price & volume
Hover for exact price & volume · green/red volume bars show up vs down days
Momentum check
Strong momentum · 4/51M
+12.74%
3M
+28.03%
6M
+74.98%
1Y
+130.66%
Where it sits in its 52-week range
91%Below 52-week high
5.4%
145.8% above the low
Momentum read
Strong
4/5 checks passed
52-wk high
₹2,454
52-wk low
₹944.9
Market cap
₹1,25,488 Cr
P/E (trailing)
93.7
Dividend yield
—
ROE
23.97%
Profit margin
17.13%
Revenue growth
33.4%
Price / Book
20.71
Debt / Equity
42.47
EPS (TTM)
24.78
Book value
₹112.16
Beta
0.67
Pulse grade: A, 88 out of 100
Momentum
A- ✓Trading above 50-day average
- ✓Trading above 200-day average
- ✓RSI in healthy 45-70 zone
- ✓Positive 3-month return
Growth
A- ✓Revenue growth above Pharma & Healthcare median (20.8%)
- ✓Revenue growing above 5%
- ✓Quarterly profits trending up
Profitability
A- ✓Return on equity above Pharma & Healthcare median (14.56%)
- ✓Return on equity above 12%
- ✓Profit margin above Pharma & Healthcare median (13.82%)
Safety
D- ✕Debt below Pharma & Healthcare median (18.57)
- ✓Debt not extreme for the sector
- ✓Less volatile than the market (beta < 1.2)
- ✕Pays a dividend
Quarterly revenue vs net profit
Sep 2026: revenue ₹2,206 crore · net profit ₹441 crore · margin 20.0%
Business quality
Intrinsic value
Analyst coverage
Who owns this company
Events, dividends & splits
Market position
Pharma & Healthcare sector
LAURUSLABS headlines
No LAURUSLABS stories right now.
LAURUSLABS filings & announcements
LAURUSLABS, historical timeline
The timeline will be ready shortly
The rest of the page is unaffected.
Risk & return, last 12 months
Volatility (ann.)
31.86%
Sharpe ratio
2.66
Sortino ratio
4.41
Max drawdown
-16.27%
Daily VaR (95%)
-2.72%
CAGR (1Y)
136.09%
Return skew
0.07
Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.
Risk profile over time
Performance at a glance
Quant tearsheet
Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.